



# MYCOBACT 2024

4-6 September

*The 11th International conference on the Pathogenesis of Mycobacterial Infections 2024*

[mycobact2024.se](http://mycobact2024.se)

# Program

11th International Conference on the  
Pathogenesis of Mycobacterial Infections  
Stockholm, Sweden, September 4-6

**JIM**

Journal of  
Internal Medicine

*Founded in 1863*



STALLMÄSTAREGÅRDEN



## Wednesday, September 4

- 10.00- Registration  
12.50-13.00 Welcome, Local organizing committee

### GENOMICS

**Chair:** *Norbert Reiling, Research Center Borstel, Germany, and Maria Lerm, Linköping University, Sweden*

- 13.00-13.35 *Stefan Niemann*, Research Center Borstel, Germany:  
Evolution and transmission of drug-resistant *M. tuberculosis* strains
- 13.40-14.15 *Kirsten Bos*, Max Planck Institute, Leipzig, Germany:  
*M. pinnipedii* in the pre-columbus era in Peru
- 14.20-14.40 Or01, *Charlotte Genestet*, Centre International de Recherche en Infectiologie (CIRI), France:  
Translational approach to decipher *M. tuberculosis* adaptation to new individuals
- 14.40-14.55 Or02, *Clara Braian*, Linköping University, Sweden:  
Genetic and epigenetic characterization of *M. abscessus* isolates of different colony morphology and their fate during macrophage infection.

- 15.00-15.30 COFFEE

### CELL BIOLOGY & METABOLISM

**Chair:** *Olena Rzhphishevska, Umeå University, Sweden, and Maria Lerm, Linköping University, Sweden*

- 15.30-16.05 *Caroline Barisch*, Center for Structural Systems Biology, Germany:  
Host-microbe interactome of *M. marinum* in model organisms
- 16.10-16.45 *Amit Singhal*, A\*STAR Infectious Diseases Labs, Singapore:  
Metabolism and TB
- 16.50-17.05 Or03, *Tiago Beites*, University of Porto, Portugal:  
Disrupting *M. tuberculosis* adaptation to host free fatty acids
- 17.05-17.20 Or04, *Nuno Rufino De Sousa*, Karolinska Institutet, Sweden:  
*M. tuberculosis* survival and replication is impaired after short-term aerosolization

### KEYNOTE TALK

- 17.20-18.00 *Katrin Mayer Barber*, Laboratory of Clinical Immunology & Microbiology, NIH, USA:  
Mechanistic insights in TB disease
- 19:00- MINGLE DINNER and POSTER SESSION

## Thursday, September 5

### HOST IMMUNE RESPONSE

**Chair:** *Simone Joosten, Leiden University Medical Centre, the Netherlands, and Brian Robertson, Imperial College London, UK*

- 08.30-09.05 *Anca Dorhoi*, Friedrich-Loeffler Institute, Germany:  
Immunoregulation in TB
- 09.10-09.45 *Olivier Neyrolles*, IPBS-Toulouse, France:  
Pathogenicity and virulence of *M. tuberculosis* in host macrophages
- 09.50-10.05 Or05, *Tobias Dallenga*, Research Center Borstel, Germany:  
*M. tuberculosis* reroutes NETosis away from PAD4 towards Gasdermin D and its prevention results in bacterial control
- 10.05-10.35 COFFEE

**Chair:** *Martin Rottenberg and Antonio G Rothfuchs, Karolinska Institutet, Sweden*

- 10.35-11.10 *Al Leslie*, Africa Health Research Institute, Durban, South Africa:  
The importance of fibroblasts in human TB granuloma
- 11.15-11.50 *Christine Stabell Benn*, University of Southern Denmark, Denmark:  
BCG vaccine-induced specific and non-specific effects
- 11.55-12.10 Or06, *Bavesh Kana*, University of the Witwatersrand, South Africa:  
A next-generation BCG candidate engineered to trigger heightened NOD-1 activation offers superior protection against TB in mice
- 12.10-13.30 LUNCH at Stallmästaregården

### DIAGNOSIS AND VACCINES

**Chair:** *Cecilia Lindestam Arlehamn, La Jolla Institute for Immunology, USA, and Susanna Brighenti, Karolinska Institutet, Sweden*

- 13.30-14.05 *Annemieke Geluk*, Leiden University, the Netherlands:  
Immunodiagnosics of mycobacterial diseases
- 14.10-14.45 *Mahdad Noursadeghi*, University College, London, UK:  
Biomarkers in diagnosis of TB
- 14.50-15.05 Or07, *Noelia Alonso Rodriguez*, Oslo University Hospital, Norway:  
Evaluation of T cell immunity in TB as potential biomarker in an anti-inflammatory personalized medicine strategy
- 15.05-15.35 COFFEE

**Chair:** *Cecilia Lindestam Arlehamn, La Jolla Institute for Immunology, USA, and Simone Joosten, Leiden University Medical Centre, the Netherlands*

- 15.35-16.10 *Iman Satti*, The Jenner Institute, University of Oxford, UK:  
Mucosal vaccines in TB
- 16.15-16.50 *Thomas Lindenstrom*, Statens Serum Institut, Denmark:  
T cell immunity with relevance for TB vaccine development
- 16.50-17.05 Or08, *Christopher Sundling*, Karolinska Institutet, Sweden:  
Evaluation of novel tests for early diagnosis of TB (ERASE-TB)

19.00- CONFERENCE DINNER

## Friday, September 6

### NEW TREATMENTS AND CLINICAL MANAGEMENT

**Chair:** *Thomas Schön, Linköping University, and Lina Davies Forsman, Karolinska Institutet, Sweden*

08.30-09.05 Jakko van Ingen, Radboud University Nijmegen Medical Center, the Netherlands:  
Management of non-tuberculous mycobacteria

09.10-09.25 Or09, Reto Guler, University of Cape Town, South Africa:  
Immunomodulatory activities of atorvastatin on PBMCs from successfully treated TB patients presenting with or without persisting lung inflammation - preliminary findings of StatinTB trial

09.30-09.45 Or10, Sanne van der Niet, Electron Microscopy Centre Amsterdam (EMCA), the Netherlands:  
From electron microscope to a potential new treatment for mycobacterial infections

09.45-10.00 Or11, Alexandre Gouzy, Weill Cornell Medicine, NY, USA:  
Shedding light on pyrazinamide's mode of action and resistance

10.05-10.35 COFFEE

**Chair:** *Brian Robertson, Imperial College London, UK, and Gabriela Godaly, Lund University, Sweden*

10.35-11.10 Robert Wilkinson, University of Cape Town, South Africa/Crick Institute, UK:  
Recent advances in TB treatment

11.15-11.50 Francisco Roca, University of Murcia, Spain:  
Host-directed therapies for TB

11.55-12.10 Maria Lerm, Linköping University, and Susanna Brighenti, Karolinska Institutet, Sweden:  
Epigenetics in *M. tuberculosis* infection with new approaches for host-directed therapies and treatment monitoring

12.10-12.15 Closure (organizing committee)

